Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Depreciation & Amortization (CF) (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Depreciation & Amortization (CF) for 7 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 18.4% to $2.1 million in Q4 2025 year-over-year; TTM through Nov 2025 was $8.7 million, a 6.63% decrease, with the full-year FY2025 number at $8.7 million, down 6.63% from a year prior.
  • Depreciation & Amortization (CF) was $2.1 million for Q4 2025 at Nurix Therapeutics, up from $2.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.5 million in Q4 2024 to a low of $600000.0 in Q1 2021.
  • A 5-year average of $1.7 million and a median of $1.9 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 107.4% in 2022, then decreased 18.4% in 2025.
  • Nurix Therapeutics' Depreciation & Amortization (CF) stood at $757000.0 in 2021, then skyrocketed by 107.4% to $1.6 million in 2022, then grew by 21.08% to $1.9 million in 2023, then soared by 34.09% to $2.5 million in 2024, then decreased by 18.4% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Depreciation & Amortization (CF) are $2.1 million (Q4 2025), $2.0 million (Q3 2025), and $2.2 million (Q2 2025).